Carol Geist
About Carol Geist
Carol Geist is the Acting Lead Global Biologics Stability at Bristol-Myers Squibb, with extensive experience in stability management and a strong background in regulatory affairs and quality assurance.
Current Role at Bristol-Myers Squibb
Carol Geist currently holds the position of Acting Lead Global Biologics Stability at Bristol-Myers Squibb. She has been with the company since August 2017. In this role, she is responsible for overseeing the stability management of biologic products on a global scale. Her extensive experience in stability management makes her a key asset to the organization.
Previous Experience at Ipsen Bioscience
Before joining Bristol-Myers Squibb, Carol Geist worked at Ipsen Bioscience as a QC Stability Manager and Regulatory CMC Sr. Manager. She held this position in Cambridge, MA, for seven months in 2017. During her tenure at Ipsen Bioscience, she gained valuable experience in quality control stability and regulatory affairs, contributing to product compliance and stability.
Professional Background at Merrimack Pharmaceuticals
Carol Geist worked as a Sr. Specialist in Stability at Merrimack Pharmaceuticals from 2015 to 2017. Based in Cambridge, MA, she played a crucial role in stability management, ensuring the reliability and consistency of pharmaceutical products. Her two-year tenure at Merrimack Pharmaceuticals helped hone her skills in stability assessments and quality assurance.
Pfizer Career Overview
Carol Geist has an extensive history with Pfizer, spanning from 2007 to 2015. She started as a Lead Investigator in Andover, MA, where she focused on stability investigations for five years. Later, she transitioned to the role of Sr. Associate Stability Specialist from 2012 to 2015. Her eight years at Pfizer provided her with a comprehensive understanding of stability management and investigative procedures.
Educational Background
Carol Geist holds a Master's degree in Quality Assurance and Regulatory Affairs from Temple University, achieved between 2010 and 2015. She also has a Bachelor's degree in Biochemistry from Brandeis University. Her academic background supports her extensive experience in quality assurance, regulatory affairs, and stability management within the pharmaceutical industry.